,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1195,1,2,,48415747,2678,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
1,1332,1,1,,49698526,2678,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
2,1469,1,1,,50112918,2678,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
3,1477,1,1,,50112918,2678,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
4,1479,1,2,,50112918,2678,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
5,1490,2,1,,50112918,2678,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
6,1766,1,1,,50112918,2678,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
7,1766,1,1,,50112918,2678,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
8,1768,1,1,,50112918,2678,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
9,1768,1,1,,50112918,2678,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
10,2062,1,2,,85209379,2678,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
11,2101,1,1,,50112918,2678,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
12,2107,1,1,,50112918,2678,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
13,2112,1,1,,50112918,2678,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
14,2240,1,1,,85788875,2678,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
15,2241,1,1,,85788875,2678,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
16,2275,1,1,,85788875,2678,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
17,2313,1,1,,85788875,2678,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
18,2314,1,2,,50112918,2678,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
19,2314,1,2,,50112918,2678,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
20,2315,1,2,,50112918,2678,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
21,2315,1,2,,50112918,2678,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
22,2322,1,1,,85788875,2678,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
23,2330,1,1,,85788875,2678,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
24,2451,1,2,,50112918,2678,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
25,2472,1,2,,50112918,2678,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
26,2517,2,1,,50112918,2678,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
27,2528,1,2,,50112918,2678,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
28,2546,1,1,,50112918,2678,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
29,2549,1,1,,50112918,2678,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
30,2551,1,1,,50112918,2678,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
31,2660,1,1,,90341832,2678,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
32,2666,1,1,,90341832,2678,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
33,2667,1,1,,90341832,2678,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
34,2668,1,1,,90341832,2678,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
35,9842,6,1,,103266652,2678,Unspecified,,,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,Other,9526560.0,
36,9843,3,6,,103266652,2678,Unspecified,,,,,Number of binding sites (n) of isolated serum protein AAG,Other,9526560.0,
37,16030,3,4,,103266652,2678,Unspecified,,,,,compound was evaluated for drug bound in plasma,Other,9526560.0,
38,22257,5,2,,103266652,2678,Unspecified,,,,,compound was evaluated for volume apparent of distribution,Other,9526560.0,
39,22294,3,5,,103266652,2678,Unspecified,,,,,delta logDoct -dod7.4,Other,9526560.0,
40,22297,3,5,,103266652,2678,Inconclusive,,,,,Delta logPoct -dod,Other,9526560.0,
41,23732,3,5,,103266652,2678,Inconclusive,,,,,Lipophilicity parameter log Pdod N,Other,9526560.0,
42,23738,3,5,,103266652,2678,Unspecified,,,,,Lipophilicity parameter log Poct A,Other,9526560.0,
43,23739,4,5,,103266652,2678,Unspecified,,,,,Lipophilicity parameter log Poct C,Other,9526560.0,
44,23938,3,5,,103266652,2678,Inconclusive,,,,,Lipophilicity parameter log Poct N (values are not experimentally accessible because of large value of KZ),Other,9526560.0,
45,23939,3,5,,103266652,2678,Unspecified,,,,,Lipophilicity parameter log Poct Z.,Other,9526560.0,
46,24350,3,4,,103266652,2678,Unspecified,,,,,compound was evaluated for half life in humans,Other,9526560.0,
47,24826,4,4,,103266652,2678,Unspecified,,,,,compound was evaluated for saturable association constant (nKa) of isolated serum protein HDL,Other,9526560.0,
48,24827,6,1,,103266652,2678,Unspecified,,,,,compound was evaluated for saturable association constant (nKa) of isolated serum protein LDL,Other,9526560.0,
49,24828,6,1,,103266652,2678,Unspecified,,,,,compound was evaluated for saturable association constant (nKa) of isolated serum protein VLDL,Other,9526560.0,
50,24829,6,1,,103266652,2678,Unspecified,,,,,compound was evaluated for saturable association constant (nKa) of isolated serum protein gamma globulins,Other,9526560.0,
51,26283,4,5,,103266652,2678,Unspecified,,,,,Partition coefficient (logD),Other,9526560.0,
52,26287,4,5,,103266652,2678,Unspecified,,,,,Partition coefficient (logD3.0),Other,9526560.0,
53,26524,3,5,,103266652,2678,Unspecified,,,,,Partition coefficient (logDdod7.4),Other,9526560.0,
54,26527,3,5,,103266652,2678,Unspecified,,,,,Partition coefficient (logD7.4),Other,9526560.0,
55,26540,4,4,,103266652,2678,Unspecified,,,,,compound was evaluated for reverse occurs for the rate constant(log K-1) at pH,Other,9526560.0,
56,26555,4,4,,103266652,2678,Unspecified,,,,,compound was evaluated for rate constant of transfer (log K1) at pH,Other,9526560.0,
57,26607,3,4,,103266652,2678,Unspecified,,,,,compound was evaluated for microscopic pKa AN value through pKa BN.,Other,9526560.0,
58,26608,3,4,,103266652,2678,Unspecified,,,,,compound was evaluated for microscopic pKa AZ value through pKa BN.,Other,9526560.0,
59,26609,3,4,,103266652,2678,Unspecified,,,,,compound was evaluated for microscopic pKa BN value by potentiometric titration in cationic/neutral mixtures,Other,9526560.0,
60,26610,3,4,,103266652,2678,Unspecified,,,,,compound was evaluated for microscopic pKa BZ value through pKa BN.,Other,9526560.0,
61,26640,3,4,,103266652,2678,Unspecified,,,,,compound was evaluated for macroscopic pKa values by potentiometric titration in menthol/water mixtures for pKa1,Other,9526560.0,
62,26758,3,4,,103266652,2678,Unspecified,,,,,compound was evaluated for tautomeric constant (KZ) value through pKa BN.,Other,9526560.0,
63,26853,3,4,,103266652,2678,Unspecified,,,,,compound was evaluated for macroscopic pKa values by potentiometric titration in menthol/water mixtures for pKa2,Other,9526560.0,
64,26879,3,4,,103266652,2678,Unspecified,,,,,compound was evaluated for macroscopic pKa values by potentiometric titration in menthol/water mixtures for pKa3,Other,9526560.0,
65,43303,3,7,,103266652,2678,Unspecified,,,,,In vitro inhibitory activity against Bradykinin receptor B2 in isolated rat ileum at 0.1 uM,Other,10509924.0,
66,78852,6,2,,103266652,2678,Active,,,0.38,IC50,Ability to inhibit histamine-induced contractions of isolated guinea pig ileum,Confirmatory,7861415.0,
67,85239,6,1,,103266652,2678,Unspecified,,,,,compound was evaluated for association constant (Ka) of isolated serum protein HSA,Other,9526560.0,
68,85240,6,1,,103266652,2678,Unspecified,,,,,compound was evaluated for association constant (Ka) of isolated serum protein HSA with FFA,Other,9526560.0,
69,85241,3,6,,103266652,2678,Unspecified,,,,,Number of binding sites (n) of isolated serum protein HSA,Other,9526560.0,
70,85242,3,6,,103266652,2678,Unspecified,,,,,Number of binding sites (n) of isolated serum protein HSA with FFA,Other,9526560.0,
71,86595,3,10,,103266652,2678,Unspecified,399889.0,100730517.0,,,In vitro inhibitory activity against histamine H1 receptor in guinea-pig ileum at 0.1 uM,Other,10509924.0,
72,87247,7,1,,103266652,2678,Active,,,0.013999999999999999,Ki,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,Confirmatory,15081022.0,
73,135327,6,1,,103266652,2678,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
74,161281,10,5,,103266652,2678,Active,7531135.0,3757.0,30.1995,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
75,165615,6,2,,103266652,2678,Unspecified,,,100.0,IC50,Test against PAF-induced aggregation of rabbit platelets in vitro,Confirmatory,7861415.0,
76,238823,8,5,,103266652,2678,Active,547645.0,3269.0,0.00589,Ki,Binding affinity for human Histamine H1 receptor in CHO K1 cells,Confirmatory,15686917.0,
77,238825,8,5,,103266652,2678,Active,547645.0,3269.0,0.013999999999999999,Ki,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Confirmatory,15482930.0,
78,240820,9,2,,103266652,2678,Unspecified,,,108.0,IC50,Inhibitory concentration against IKr potassium channel,Confirmatory,15324906.0,
79,241255,8,7,,103266652,2678,Inconclusive,126407.0,240.0,,,Inhibition of 5-lipoxygenase activity in human whole blood assay; not tested,Other,15482930.0,
80,243151,7,2,,103266652,2678,Active,,,30.1995,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
81,251600,3,3,,103266652,2678,Unspecified,,,,,Percentage reduction central nervous system depression in guinea pig by compound,Other,15780625.0,
82,252138,3,3,,103266652,2678,Unspecified,,,,,Percentage protection of guinea pigs from histamine induced bronchospasm by compound,Other,15780625.0,
83,254274,8,5,,103266652,2678,Active,547645.0,3269.0,0.013999999999999999,Ki,Inhibition constant against histamine H1 receptor,Confirmatory,16220969.0,
84,276169,11,2,,103266652,2678,Unspecified,7531135.0,3757.0,30.0,IC50,Inhibition of human ERG potassium channel in HEK293 cells by patch clamp assay,Confirmatory,16931010.0,
85,281733,6,8,,103266652,2678,Unspecified,30581059.0,15465.0,,,Ex vivo displacement of [3H]mepyramine from brain histamine H1 receptor in orally dosed Swiss Albino mouse,Other,15566302.0,
86,281739,3,3,,103266652,2678,Inactive,,,,,"Effect on QT interval prolongation in Dunkin-Hartley guinea pigs at 3 mg/kg, iv",Other,15566302.0,
87,281740,3,11,,103266652,2678,Unspecified,116241312.0,1576.0,,,Inhibition of CYP3A4 in human microsomes at 25 uM,Other,15566302.0,
88,281741,6,2,,103266652,2678,Unspecified,,,,,Inhibition of increase in histamine-induced cutaneous vascular permeability in orally dosed Wistar rat model after 1 hrs,Other,15566302.0,
89,386623,4,8,,103266652,2678,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
90,408340,8,5,,103266652,2678,Active,7531135.0,3757.0,30.1995,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
91,434959,1,1,,85788875,2678,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
92,445445,7,1,,103266652,2678,Unspecified,,,,,Permeability at pH 6.5 by PAMPA method,Other,19947605.0,
93,445446,3,4,,103266652,2678,Unspecified,,,,,Oral bioavailability in human,Other,19947605.0,
94,463106,1,2,,90341832,2678,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
95,481439,3,4,,103266652,2678,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
96,481442,3,6,,103266652,2678,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
97,485281,1,1,,50112918,2678,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
98,485290,1,1,,50112918,2678,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
99,485295,1,2,,90341832,2678,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
100,485297,1,1,,90341832,2678,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
101,485298,1,1,,90341832,2678,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
102,485313,1,2,,90341832,2678,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
103,485342,1,2,,90341832,2678,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
104,485345,1,2,,90341832,2678,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
105,485366,1,2,,90341832,2678,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
106,485368,1,2,,90341832,2678,Inconclusive,72386991.0,3656265.0,37.933,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
107,485395,1,2,,92290962,2678,Inactive,150392496.0,,,,A screen for compounds that inhibit the activity of Staphylococcus aureus DNA helicase,Other,,
108,488772,1,1,,90341832,2678,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
109,488773,1,2,,90341832,2678,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
110,488816,1,1,,90341832,2678,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
111,488837,1,1,,90341832,2678,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
112,488949,1,2,,90341832,2678,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
113,488953,1,1,,90341832,2678,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
114,488978,1,1,,90341832,2678,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
115,488981,1,1,,90341832,2678,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
116,488982,1,1,,90341832,2678,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
117,488983,1,1,,90341832,2678,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
118,492967,1,2,,92290962,2678,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
119,493106,1,1,,90341832,2678,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
120,493107,1,1,,90341832,2678,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
121,493153,1,1,,90341832,2678,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
122,493153,1,1,,90341832,2678,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
123,493162,1,2,,92290962,2678,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
124,493164,1,2,,90341832,2678,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
125,493164,1,2,,90341832,2678,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
126,493164,1,2,,90341832,2678,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
127,500222,7,5,,103266652,2678,Active,547645.0,3269.0,0.05012,Ki,Displacement of [3H]mepyramine from human wild-type histamine H1 receptor expressed in COS-7 cells by liquid scintillation counting,Confirmatory,16408006.0,
128,500223,4,3,,103266652,2678,Active,,,0.05012,Ki,Displacement of [3H]mepyramine from human histamine H1 receptor S3.36A mutant expressed in COS-7 cells by liquid scintillation counting,Confirmatory,16408006.0,
129,500224,4,3,,103266652,2678,Active,,,0.03162,Ki,Displacement of [3H]mepyramine from human histamine H1 receptor S3.36C mutant expressed in COS-7 cells by liquid scintillation counting,Confirmatory,16408006.0,
130,500225,4,3,,103266652,2678,Active,,,0.03162,Ki,Displacement of [3H]mepyramine from human histamine H1 receptor S3.36T mutant expressed in COS-7 cells by liquid scintillation counting,Confirmatory,16408006.0,
131,500226,4,3,,103266652,2678,Active,,,0.07943,Ki,Displacement of [3H]mepyramine from human histamine H1 receptor N7.45C mutant expressed in COS-7 cells by liquid scintillation counting,Confirmatory,16408006.0,
132,500227,4,3,,103266652,2678,Active,,,0.0631,Ki,Displacement of [3H]mepyramine from human histamine H1 receptor N7.45Q mutant expressed in COS-7 cells by liquid scintillation counting,Confirmatory,16408006.0,
133,500228,4,3,,103266652,2678,Active,,,0.0631,Ki,Displacement of [3H]mepyramine from human histamine H1 receptor N7.45S mutant expressed in COS-7 cells by liquid scintillation counting,Confirmatory,16408006.0,
134,504327,1,1,,50112918,2678,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
135,504327,1,1,,90341832,2678,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
136,504332,1,1,,90341832,2678,Inconclusive,168985070.0,,23.7781,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
137,504536,1,1,,90341832,2678,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
138,504547,1,1,,90341832,2678,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
139,504548,1,2,,90341832,2678,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
140,504770,1,2,,92290962,2678,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
141,504810,1,2,,90341832,2678,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
142,504812,1,2,,90341832,2678,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
143,504836,1,2,,90341832,2678,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
144,504845,1,1,,90341832,2678,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
145,504847,1,1,,50112918,2678,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
146,504847,1,1,,90341832,2678,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
147,504865,1,1,,90341832,2678,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
148,540256,1,2,,90341832,2678,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
149,540276,1,2,,50112918,2678,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
150,540276,1,2,,50112919,2678,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
151,540276,1,2,,50112920,2678,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
152,540276,1,2,,90341832,2678,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
153,540299,1,2,,92290962,2678,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
154,576612,7,5,,103266652,2678,Active,7531135.0,3757.0,31.6228,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
155,588211,2,3,,103266652,2678,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
156,588212,2,3,,103266652,2678,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
157,588213,2,3,,103266652,2678,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
158,588214,2,3,,103266652,2678,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
159,588215,2,3,,103266652,2678,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
160,588216,2,3,,103266652,2678,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
161,588217,2,3,,103266652,2678,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
162,588218,2,3,,103266652,2678,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
163,588219,2,3,,103266652,2678,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
164,588349,1,1,,90341832,2678,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
165,588378,1,1,,90341832,2678,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
166,588453,1,1,,90341832,2678,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
167,588456,1,1,,90341832,2678,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
168,588519,1,2,,92290962,2678,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
169,588579,1,1,,50112918,2678,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
170,588579,1,1,,90341832,2678,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
171,588795,1,1,,90341832,2678,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
172,588985,1,9,,103266652,2678,Unspecified,313104182.0,6582.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OCT2",Other,20190787.0,
173,602314,1,2,,92290962,2678,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
174,602332,1,1,,50112918,2678,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
175,602332,1,1,,90341832,2678,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
176,624146,1,1,,90341832,2678,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
177,624147,1,1,,90341832,2678,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
178,624148,1,2,,90341832,2678,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
179,624149,1,1,,90341832,2678,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
180,624156,1,1,,85788875,2678,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
181,624349,1,2,,121362416,2678,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
182,624455,1,1,,90341832,2678,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
183,625279,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
184,625280,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
185,625281,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
186,625282,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
187,625283,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
188,625284,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
189,625285,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
190,625286,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
191,625287,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
192,625288,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
193,625289,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
194,625290,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
195,625291,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
196,625292,1,3,,103266652,2678,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
197,651635,1,3,,90341832,2678,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
198,651828,1,2,,121362416,2678,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
199,652106,1,1,,90341832,2678,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
200,653693,8,2,,103266652,2678,Unspecified,218511853.0,7010.0,90.0,Kd,Binding affinity to human recombinant Tie2 by SPR assay,Confirmatory,22406116.0,
201,653696,1,8,,103266652,2678,Active,218511853.0,7010.0,,,Displacement of angiopoietin 1 from human recombinant Tie2 at 50 to 100 uM,Other,22406116.0,
202,686977,2,1,,49698526,2678,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
203,699539,1,7,,103266652,2678,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
204,699540,1,7,,103266652,2678,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
205,699541,1,7,,103266652,2678,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
206,720532,1,1,,50112918,2678,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
207,720533,1,1,,50112918,2678,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
208,720538,1,2,,90341832,2678,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
209,720554,1,3,,121362416,2678,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
210,720559,1,2,,90341832,2678,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
211,720572,1,2,,90341832,2678,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
212,720573,1,2,,90341832,2678,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
213,720641,1,2,,92290962,2678,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
214,721753,1,6,,103266652,2678,Unspecified,74731723.0,55244.0,,,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay,Other,23241029.0,
215,721754,2,5,,103266652,2678,Unspecified,74731723.0,55244.0,500.0,IC50,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
216,743205,1,1,,90341832,2678,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
217,743205,1,1,,90341832,2678,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
218,743206,1,1,,90341832,2678,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
219,743206,1,1,,90341832,2678,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
220,743207,1,1,,90341832,2678,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
221,743207,1,1,,90341832,2678,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
222,743244,1,1,,90341832,2678,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
223,743268,1,1,,172080819,2678,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
224,743270,1,1,,172080819,2678,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
225,743271,1,1,,172080819,2678,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
226,743272,1,1,,172080819,2678,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
227,743344,1,1,,174007233,2678,Inactive,,,4.7277,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
228,743345,1,1,,174007233,2678,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
229,743346,1,1,,174007233,2678,Inactive,,,14.9502,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
230,743347,1,1,,174007233,2678,Inactive,,,0.1058,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
231,1053175,2,1,,178126056,2678,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
232,1079931,1,1,,103266652,2678,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
233,1079932,1,1,,103266652,2678,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
234,1079933,1,1,,103266652,2678,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
235,1079934,1,1,,103266652,2678,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
236,1079935,1,1,,103266652,2678,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
237,1079936,1,1,,103266652,2678,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
238,1079937,1,1,,103266652,2678,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
239,1079938,1,1,,103266652,2678,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
240,1079939,1,1,,103266652,2678,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
241,1079940,1,1,,103266652,2678,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
242,1079941,1,1,,103266652,2678,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
243,1079942,1,1,,103266652,2678,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
244,1079943,1,1,,103266652,2678,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
245,1079944,1,1,,103266652,2678,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
246,1079945,1,1,,103266652,2678,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
247,1079946,1,1,,103266652,2678,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
248,1079947,1,1,,103266652,2678,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
249,1079948,1,1,,103266652,2678,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
250,1079949,1,1,,103266652,2678,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
251,1097336,1,3,,103266652,2678,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
252,1159386,1,2,,103266652,2678,Unspecified,,,,,ASTRAZENECA: Most basic pKa value (pKa B1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2.,Other,,
253,1159387,1,2,,103266652,2678,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
254,1159389,1,2,,103266652,2678,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
255,1159391,1,2,,103266652,2678,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole dog plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
256,1159393,1,2,,103266652,2678,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole guinea pig plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
257,1159394,1,2,,103266652,2678,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
258,1159399,1,2,,103266652,2678,Unspecified,,,,,ASTRAZENECA: Most acidic pKa value (pKa A1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Acids: <= 11.,Other,,
259,1159524,1,1,,50112918,2678,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
260,1159580,2,1,,268735097,2678,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
261,1159583,2,1,,178126056,2678,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
262,1159607,2,1,,312309797,2678,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
263,1189129,1,1,,103266652,2678,Unspecified,,,119.9,IC50,"DNDI: Chagas in Vitro, 96 hour",Confirmatory,,
264,1189130,1,1,,103266652,2678,Unspecified,,,148.82,IC50,"DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells",Confirmatory,,
265,1189131,1,1,,103266652,2678,Unspecified,,,70.53,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in mouse macrophages (infected-amastigotes)",Confirmatory,,
266,1189133,1,1,,103266652,2678,Unspecified,,,99.45,IC50,"DNDI: HAT in Vitro, 72 hour",Confirmatory,,
267,1189134,1,1,,103266652,2678,Unspecified,,,186.43,IC50,"DNDI: Leish (axenic) in Vitro, 72 hour",Confirmatory,,
268,1189135,1,1,,103266652,2678,Unspecified,,,70.53,IC50,"DNDI: Leish (macro) in Vitro, 96 hour",Confirmatory,,
269,1189136,1,1,,103266652,2678,Active,,,19.98,IC50,"DNDI: Malaria in Vitro, 72 hour",Confirmatory,,
270,1193492,1,1,,103266652,2678,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method",Other,25740159.0,
271,1193493,1,1,,103266652,2678,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
272,1193494,1,1,,103266652,2678,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
273,1193495,1,1,,103266652,2678,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
274,1193496,1,1,,103266652,2678,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method",Other,25740159.0,
275,1193497,1,1,,103266652,2678,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method",Other,25740159.0,
276,1193498,1,1,,103266652,2678,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method",Other,25740159.0,
277,1193499,1,1,,103266652,2678,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method",Other,25740159.0,
278,1212314,1,1,,103266652,2678,Unspecified,,,500.0,IC50,Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins,Confirmatory,23378628.0,
279,1212341,1,1,,103266652,2678,Unspecified,,,,,Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay,Other,23378628.0,
280,1221956,1,1,,103266652,2678,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
281,1221957,1,1,,103266652,2678,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
282,1221958,1,1,,103266652,2678,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
283,1221960,1,1,,103266652,2678,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
284,1221961,1,1,,103266652,2678,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
285,1221962,1,1,,103266652,2678,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
286,1221963,1,1,,103266652,2678,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
287,1221964,1,1,,103266652,2678,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
288,1221965,1,1,,103266652,2678,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
289,1221982,1,1,,103266652,2678,Unspecified,,,,,Fraction absorbed in human,Other,21051535.0,
290,1224824,1,1,,174007233,2678,Inactive,,,11.7704,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
291,1224825,1,1,,174007233,2678,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
292,1224857,2,1,,174007233,2678,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
293,1224859,2,1,,90341832,2678,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
294,1224859,2,1,,174007233,2678,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
295,1224863,1,1,,176484197,2678,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
296,1224863,1,1,,176484914,2678,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
297,1224863,1,1,,316919109,2678,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
298,1259252,1,1,,174007233,2678,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
299,1259253,1,1,,174007233,2678,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
300,1259255,1,1,,174007233,2678,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
301,1259256,1,1,,174007233,2678,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
302,1259309,1,1,,178126056,2678,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
303,1259310,1,1,,104170194,2678,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
304,1259311,1,1,,178126056,2678,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
305,1259325,1,2,,336956316,2678,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
306,1259406,1,1,,363920250,2678,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
307,1259406,1,1,1.0,363920250,2678,Inactive,26638650.0,3778.0,0.0593778,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
308,1259406,1,1,2.0,363920250,2678,Inactive,4758626.0,3779.0,0.0627061,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
309,1259406,1,1,3.0,363920250,2678,Active,5031823.0,10242.0,0.0743043,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
310,1259406,1,1,4.0,363920250,2678,Inactive,26051275.0,27345.0,0.0510599,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
311,1259406,1,1,5.0,363920250,2678,Inactive,160410009.0,389816.0,0.0147683,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
312,1259406,1,1,6.0,363920250,2678,Inactive,26638650.0,3778.0,0.030352800000000003,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
313,1259406,1,1,7.0,363920250,2678,Inactive,4758626.0,3779.0,0.109079,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
314,1259406,1,1,8.0,363920250,2678,Inactive,5031823.0,10242.0,0.056035400000000006,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
315,1259406,1,1,9.0,363920250,2678,Inactive,26051275.0,27345.0,0.0338096,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
316,1259406,1,1,10.0,363920250,2678,Inactive,5031823.0,10242.0,-0.0638921,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
317,1259413,1,2,,104170194,2678,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
318,1259416,1,2,,340079673,2678,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
319,1259416,1,2,,375178352,2678,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
320,1259421,1,1,,340079673,2678,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
321,1259421,1,1,,375178352,2678,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
322,1259423,1,2,,354917995,2678,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
323,1259423,1,2,,354940693,2678,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
324,1259423,1,2,,354963448,2678,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
325,1259423,1,2,,355019390,2678,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
